The RSI Oscillator for HLOSF moved out of oversold territory on December 02, 2024. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 3 similar instances when the indicator left oversold territory. In of the 3 cases the stock moved higher. This puts the odds of a move higher at .
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Momentum Indicator moved above the 0 level on December 03, 2024. You may want to consider a long position or call options on HLOSF as a result. In of 12 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for HLOSF just turned positive on December 03, 2024. Looking at past instances where HLOSF's MACD turned positive, the stock continued to rise in of 6 cases over the following month. The odds of a continued upward trend are .
The Aroon Indicator for HLOSF entered a downward trend on November 25, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.760) is normal, around the industry mean (14.294). P/E Ratio (0.000) is within average values for comparable stocks, (87.370). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.766). HLOSF has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (31.646) is also within normal values, averaging (256.769).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. HLOSF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HLOSF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Industry Biotechnology
A.I.dvisor tells us that HLOSF and BRTX have been poorly correlated (+23% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that HLOSF and BRTX's prices will move in lockstep.
Ticker / NAME | Correlation To HLOSF | 1D Price Change % | ||
---|---|---|---|---|
HLOSF | 100% | N/A | ||
BRTX - HLOSF | 23% Poorly correlated | -9.03% | ||
LGVN - HLOSF | 22% Poorly correlated | -7.30% | ||
ENTBF - HLOSF | 7% Poorly correlated | N/A | ||
CPMV - HLOSF | 5% Poorly correlated | N/A | ||
SLN - HLOSF | 3% Poorly correlated | -2.76% | ||
More |